Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Or
Select a campus/region
(352) 294-5480

Kartik Cherabuddi, MD, FACP, FIDSA

Infectious Disease Specialist

Photo of Kartik Cherabuddi
(352) 294-5480 MyUFHealth

Research at a glance

Top areas of exploration

  • Anti-Bacterial Agents , 10 publications
  • COVID-19 , 5 publications
  • Vancomycin , 3 publications
  • Cefepime , 3 publications

Research activity

64 publications

1,014 citations

Why is this important?

Focus

Multidrug resistant infections

Antimicrobial alternatives to antibiotics

Therapeutic drug monitoring and personalized medicine

Emerging global infections

NTM infections in Transplant patients

Infectious disease fellow, Internal medicine resident and Medical student education

Active clinical trials

DOTS (20-0002)

This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of care antibiotic therapy for the completion of therapy in patients with complicated…

Investigator
Kartik Cherabuddi
Status
Accepting Candidates
Ages
18 Years - 99 Years
Sexes
All

My publications

64 publications

2022

Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.

Antimicrobial agents and chemotherapy

PubMed • Publisher's site

2022

Development of a Prediction Model for Antibiotic-Resistant Urinary Tract Infections Using Integrated Electronic Health Records from Multiple Clinics in North-Central Florida.

Infectious diseases and therapy

PubMed • Publisher's site

2022

Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial.

JAMA network open

PubMed • Publisher's site

2022

Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

PubMed • Publisher's site

2022

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI).

Antimicrobial stewardship & healthcare epidemiology : ASHE

PubMed • Publisher's site